Tasman Therapeutics has announced a multi-year strategic partnership with Osmind, the market leader in technology and real-world evidence for psychiatry, to support its R-107 Ketamine program. The partnership will support Tasman's ROCKET phase 3 pivotal program and lay the groundwork for a highly differentiated technology and data-enabled commercialisation strategy for R-107's potential future launch.

Osmind powers the largest network of independent psychiatry practices in the US that offer next-generation treatments for treatment-resistant depression, including intravenous ketamine, intranasal esketamine, and other related therapies. Through its proprietary Electronic Health Record (EHR) and Artificial Intelligence (AI) platform, Osmind has built the world's largest real-world dataset of patients treated with rapid-acting psychopharmacologic drugs, positioning it as the leading research and commercial partner for companies developing novel treatments in this therapeutic class.

In the near term, Tasman will leverage Osmind's real-world data and clinical network to support the design and execution of the ROCKET phase 3 program and pipeline expansion. This includes helping optimise trial design, safety characterisation, and regulatory strategy, as well as clinical trial site identification and awareness support across Osmind's national network of interventional psychiatry practices.

Looking ahead to R-107's potential approval and launch, Osmind will accelerate Tasman's commercialisation through unique, technology-enabled infrastructure optimised with data and artificial intelligence for patient care and compliance. This differentiated approach will encompass longitudinal evidence generation, a consumer-facing patient app, a longitudinal data registry, and a clinician network model supporting both in-person and at-home care.

Dan Browne, CEO, Tasman Therapeutics, "As we advance R-107 through phase 3 and toward what we believe can be the first and only oral, at-home monotherapy for treatment-resistant depression, having a strategic partner with Osmind's data, technology footprint, clinical network, and operational and artificial intelligence expertise gives us a meaningful advantage–both in how we execute our trials and in how we think about safely bringing R-107 to patients at scale in a truly innovative way."

Jimmy Qian, Co-Founder and President, Osmind, said, "Tasman is developing what we believe will become one of the most important new treatments in psychiatry. An oral, effective, safe, at-home treatment option for depression would be exactly the kind of innovation patients need. We've spent years building the infrastructure, technology, datasets, and clinical relationships that sit at the center of the treatment landscape for rapid-acting psychopharmacologic drugs. We look forward to leveraging these assets to support Tasman through Phase 3 today to the technology and care delivery model that will define how patients experience R-107 tomorrow."